Please forgive the dated (2018-era) graphic, but the early 2018 efficacy beat, by GSK's Shingrix® offering remains at least as important as the fact of the recent Third Circuit dismissal.
That is, Merck's offering was likely not as effective as other competitors'. Even so, it is immaterial good news for Rahway, that these purported "vaccine injury" suits are likely at an end [A Supremes appeal would be pure-folly at this point.] Here's Fierce on it all (as of yesterday):
. . .After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax.
Late last week, the U.S. Court of Appeals for the Third Circuit tossed an appeal to resurrect certain lawsuits claiming Merck’s popular shot caused patients to develop shingles.
The appeals court made its decision after the plaintiffs filed a voluntary dismissal some two years after logging a loss in Pennsylvania, court documents show. . . .
Not likely to change NYSE trading ranges at all. . . but now you know. Onward to tonight, off the coast of South America, and a fireball lighting up the inky Atlantic Ocean's sky. Grin.
नमस्ते
1 comment:
Once just now -- at 4:16 pm... smiling right at you... cool and cloudy here today... like that first time in October -- at Five Points... grin.
Post a Comment